Gary E. Duncan mainly focuses on Neuroscience, NMDA receptor, Dopamine, Schizophrenia and Antipsychotic. His work in the fields of Neuroscience, such as Nucleus accumbens, intersects with other areas such as Progressive disorder and Identification. His research investigates the connection with NMDA receptor and areas like Pharmacology which intersect with concerns in Hippocampus and Ketamine.
The Dopamine portion of his research involves studies in Internal medicine and Endocrinology. His Schizophrenia study integrates concerns from other disciplines, such as Psychosis and Neurotransmitter. While the research belongs to areas of Antipsychotic, Gary E. Duncan spends his time largely on the problem of Clozapine, intersecting his research to questions surrounding Atypical antipsychotic and Haloperidol.
His primary scientific interests are in Endocrinology, Internal medicine, Pharmacology, Neuroscience and NMDA receptor. In the field of Endocrinology, his study on Hippocampus, Central nervous system and Dopamine overlaps with subjects such as Imipramine. Internal medicine and Binding site are commonly linked in his work.
His Pharmacology research incorporates elements of Clozapine, Haloperidol, Ketamine, Olanzapine and Antipsychotic. Neuroscience is closely attributed to Schizophrenia in his work. His NMDA receptor study combines topics from a wide range of disciplines, such as Glutamate receptor and Psychosis.
His main research concerns Pharmacology, NMDA receptor, Neuroscience, Genetic model and Antipsychotic. His Pharmacology study combines topics in areas such as Haloperidol, Clozapine, Olanzapine and Hippocampal formation. He has researched NMDA receptor in several fields, including Glutamate receptor and Psychosis.
Within one scientific family, he focuses on topics pertaining to Prepulse inhibition under Psychosis, and may sometimes address concerns connected to Gating. His Antipsychotic study contributes to a more complete understanding of Schizophrenia. His studies in Schizophrenia integrate themes in fields like Dopamine receptor and Drug development, Drug.
His primary areas of investigation include Psychosis, Schizophrenia, NMDA receptor, Neuroscience and Prepulse inhibition. His Psychosis study frequently intersects with other fields, such as Pharmacology. His Pharmacology research is multidisciplinary, incorporating elements of Aripiprazole and Dopamine receptor.
His research in the fields of Antipsychotic overlaps with other disciplines such as Mechanism of action. His biological study spans a wide range of topics, including Discrimination learning and GRIN1. His Prepulse inhibition research incorporates themes from Haloperidol, Clozapine and Gating.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
Seiya Miyamoto;Gary E Duncan;Christine E Marx;Jeffrey A Lieberman.
Molecular Psychiatry (2005)
Neuroanatomical characterization of Fos induction in rat behavioral models of anxiety.
Gary E. Duncan;Darin J. Knapp;George R. Breese.
Brain Research (1996)
Topographic patterns of brain activity in response to swim stress: assessment by 2-deoxyglucose uptake and expression of Fos-like immunoreactivity
GE Duncan;KB Johnson;GR Breese.
The Journal of Neuroscience (1993)
Ontogeny of D1A and D2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding.
U.B. Schambra;G.E. Duncan;G.R. Breese;M.G. Fornaretto.
Serotonergic basis of antipsychotic drug effects in schizophrenia
Jeffrey A Lieberman;Richard B Mailman;Gary Duncan;Lin Sikich.
Biological Psychiatry (1998)
6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
G R Breese;G E Duncan;T C Napier;S C Bondy.
Journal of Pharmacology and Experimental Therapeutics (1987)
Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function.
Gary E Duncan;Sheryl S Moy;Antonio Perez;Dawn M Eddy.
Behavioural Brain Research (2004)
Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection
Jeffrey A. Lieberman;Frank P. Bymaster;Herbert Y. Meltzer;Ariel Y. Deutch.
Pharmacological Reviews (2008)
An integrated view of pathophysiological models of schizophrenia.
Gary E Duncan;Brian B Sheitman;Jeffery A Lieberman.
Brain Research Reviews (1999)
Molecular basis for regionally specific action of ethanol on gamma-aminobutyric acidA receptors: generalization to other ligand-gated ion channels.
H E Criswell;P E Simson;G E Duncan;T J McCown.
Journal of Pharmacology and Experimental Therapeutics (1993)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: